{
    "4 17 2025": {
        "importantArticles": [
            {
                "headline": "Investing.com -- Novo Nordisk A/S (NYSE:NVO) shares fell as much as 8% in Thursday trading after news emerged about a competitor\u2019s successful drug trial.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7184",
                "source": "Investing.com",
                "ticker": "NVO",
                "title": "Novo Nordisk shares slump following Eli Lilly\u2019s weight-loss pill success",
                "url": "https://finance.yahoo.com/news/novo-nordisk-shares-slump-following-140751424.html"
            },
            {
                "headline": "U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer's stock.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5719",
                "source": "Investopedia",
                "ticker": "NVO",
                "title": "Novo Nordisk Stock Drops on Eli Lilly Oral Weight-Loss Drug Success, Downgrade",
                "url": "https://finance.yahoo.com/news/novo-nordisk-stock-drops-eli-175412305.html"
            },
            {
                "headline": "Eli Lilly surged during Thursday's trading session after promising test results came out of the pharmaceutical company's ongoing weight-loss pill trial. Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination with Host Josh Lipton, Unlimited co-founder, CEO, and chief investment officer Bob Elliott, and Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani to explain why the test results sent the pharmaceutical stock soaring. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3182",
                "source": "Yahoo Finance Video",
                "ticker": "NVO",
                "title": "How Eli Lilly's GLP-1 pill could transform the weight-loss space",
                "url": "https://finance.yahoo.com/video/eli-lillys-glp-1-pill-202940776.html"
            },
            {
                "headline": "We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that Jim Cramer discussed recently. On Friday, Mad Money host Jim Cramer addressed growing concerns in the market as tensions between the [\u2026]",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.6369",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "\u201cI Am a Buyer\u201d: Jim Cramer Backs Novo Nordisk (NVO) After Its Sharp Decline",
                "url": "https://finance.yahoo.com/news/am-buyer-jim-cramer-backs-020413895.html"
            },
            {
                "headline": "Eli Lilly stock jetted higher Thursday after the company said its diabetes and weight-loss pill helped patients lose up to 16 pounds.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4019",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Eli Lilly Rockets 14% After Solidifying Its Lead For A Weight-Loss Pill",
                "url": "https://finance.yahoo.com/m/5523c7a4-d163-34a1-a4cc-5421457b13c3/eli-lilly-rockets-14-after.html"
            },
            {
                "headline": "Investing.com -- BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to \u201cMarket Perform\u201d from \u201cOutperform\u201d and cut its price target to $64, saying the Danish drugmaker\u2019s early lead in the obesity drug market is being overtaken by rival Eli Lilly\u2019s rapidly advancing pipeline.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2732",
                "source": "Investing.com",
                "ticker": "NVO",
                "title": "Novo Nordisk downgraded by BMO as Eli Lilly gains ground in weight-loss drug race",
                "url": "https://finance.yahoo.com/news/novo-nordisk-downgraded-bmo-eli-184129564.html"
            }
        ],
        "avgScore": 0.04693333333333332
    },
    "4 16 2025": {
        "importantArticles": [
            {
                "headline": "Despite its expensive valuation, we suggest investors hold LLY stock as the company boasts solid growth prospects.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?",
                "url": "https://finance.yahoo.com/news/eli-lilly-stock-down-8-110500046.html"
            },
            {
                "headline": "We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls\u2019 thesis on NVO. Novo Nordisk A/S (NVO)\u2019s share was trading at $64.49 as of April 15th. NVO\u2019s trailing and forward P/E were 18.76 and 15.41 respectively according to Yahoo Finance. Novo Nordisk, a dominant [\u2026]",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Novo Nordisk A/S (NVO): A Bull Case Theory",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-bull-case-183735432.html"
            },
            {
                "headline": "Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide offerings.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3612",
                "source": "Pharmaceutical Technology",
                "ticker": "NVO",
                "title": "The GLP-1 drug shortage is over. What\u2019s next for the compounders?",
                "url": "https://finance.yahoo.com/news/glp-1-drug-shortage-over-143913812.html"
            },
            {
                "headline": "Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide offerings.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3612",
                "source": "Pharmaceutical Technology",
                "ticker": "NVO",
                "title": "The GLP-1 drug shortage is over. What\u2019s next for the compounders?",
                "url": "https://finance.yahoo.com/news/glp-1-drug-shortage-over-143913812.html"
            },
            {
                "headline": "We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls\u2019 thesis on NVO. Novo Nordisk A/S (NVO)\u2019s share was trading at $64.49 as of April 15th. NVO\u2019s trailing and forward P/E were 18.76 and 15.41 respectively according to Yahoo Finance. Novo Nordisk, a dominant [\u2026]",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Novo Nordisk A/S (NVO): A Bull Case Theory",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-bull-case-183735432.html"
            },
            {
                "headline": "Despite its expensive valuation, we suggest investors hold LLY stock as the company boasts solid growth prospects.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?",
                "url": "https://finance.yahoo.com/news/eli-lilly-stock-down-8-110500046.html"
            }
        ],
        "avgScore": 0.28529999999999994
    },
    "4 15 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big American [\u2026]",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9274",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Is Novo Nordisk A/S (NVO) the Best Pharma Stock to Buy for Long Term Growth?",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-best-pharma-185200431.html"
            },
            {
                "headline": "Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7269",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback",
                "url": "https://finance.yahoo.com/news/nvo-lly-gpcr-vktx-stocks-140000975.html"
            },
            {
                "headline": "Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts \u201climited reaction\u201d in Pfizer\u2019s shares following the news, JPMorgan tells investors that the decision is \u201cmostly a positive\u201d for Structure and Viking, both developing drugs in the",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5267",
                "source": "TipRanks",
                "ticker": "NVO",
                "title": "Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill",
                "url": "https://finance.yahoo.com/news/smaller-obesity-drugmakers-jump-pfizer-143525028.html"
            },
            {
                "headline": "PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4215",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Pfizer Halts Obesity Pill Development Amid Safety Concerns",
                "url": "https://finance.yahoo.com/news/pfizer-halts-obesity-pill-development-165700605.html"
            },
            {
                "headline": "On Monday, Novo Nordisk A/S (NYSE:NVO) said it had become aware of several hundred units of Ozempic (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the U.S. The seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits 51746517. Lot number PAR0362 is an authentic lot number. Only when the lot number is coupled with the eight digits 51746517 it is counterfeit and should not be used. Als",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.296",
                "source": "Benzinga",
                "ticker": "NVO",
                "title": "Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts",
                "url": "https://finance.yahoo.com/news/counterfeit-ozempic-identified-us-supply-202035878.html"
            },
            {
                "headline": "Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts \u201climited reaction\u201d in Pfizer\u2019s shares following the news, JPMorgan tells investors that the decision is \u201cmostly a positive\u201d for Structure and Viking, both developing drugs in the",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5267",
                "source": "TipRanks",
                "ticker": "NVO",
                "title": "Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill",
                "url": "https://finance.yahoo.com/news/smaller-obesity-drugmakers-jump-pfizer-143525028.html"
            }
        ],
        "avgScore": 0.41109999999999997
    },
    "4 14 2025": {
        "importantArticles": [
            {
                "headline": "HYDERABAD (Reuters) -The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its availability, with some Indian doctors fielding hundreds of calls about the medicine, according to a Reuters survey.  The survey of 18 doctors, patients and weight-loss clinic operators follows the U.S. drugmaker's market entry ahead of Danish obesity drug rival Novo Nordisk into a nation expected to have the second-largest population of overweight or obese people by 2050.  \"Since the launch of Mounjaro, we have seen a remarkable increase in customer interest,\" said Suryansh Kumar, founder of  Delhi-based weight management services provider Elevate Now.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8176",
                "source": "Reuters",
                "ticker": "NVO",
                "title": "Eli Lilly's Mounjaro launch in India ignites wave of weight-loss enquiries",
                "url": "https://finance.yahoo.com/news/eli-lillys-mounjaro-launch-india-194918761.html"
            },
            {
                "headline": "The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4019",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Tap Into the Silver Economy Boom With These Aging Demographics Stocks",
                "url": "https://finance.yahoo.com/news/tap-silver-economy-boom-aging-190000247.html"
            },
            {
                "headline": "Pfizer ends its most advanced clinical trial of an obesity pill to compete in the hot GLP-1 space.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3167",
                "source": "Yahoo Finance",
                "ticker": "NVO",
                "title": "Pfizer discontinues GLP-1 pill trial, stock trades flat",
                "url": "https://finance.yahoo.com/news/pfizer-discontinues-glp-1-pill-trial-stock-trades-flat-135330797.html"
            },
            {
                "headline": "Pfizer (PFE) announced Monday that it is ending development of its daily weight-loss pill following a liver injury to a patient participating in a trial.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4215",
                "source": "Quartz",
                "ticker": "NVO",
                "title": "Pfizer just had a big setback in its race for an Ozempic competitor",
                "url": "https://finance.yahoo.com/news/pfizer-just-had-big-setback-145553640.html"
            },
            {
                "headline": "Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial experienced a \"liver injury.\"",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.296",
                "source": "Investopedia",
                "ticker": "NVO",
                "title": "Pfizer Halts Development of Obesity Drug After Patient Sustains 'Liver Injury'",
                "url": "https://finance.yahoo.com/news/pfizer-halts-development-obesity-drug-141357676.html"
            },
            {
                "headline": "Pfizer bows, but is not entirely out of the GLP-1 race.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Motley Fool",
                "ticker": "NVO",
                "title": "Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today",
                "url": "https://finance.yahoo.com/news/why-eli-lilly-novo-nordisk-151230600.html"
            }
        ],
        "avgScore": 0.13645
    },
    "4 11 2025": {
        "importantArticles": [
            {
                "headline": "Through all the market madness of the past two years, there has been one truth universally acknowledged by the analysts who track healthcare stocks on Wall Street: that the market for the new, effective obesity drugs will be even bigger than anyone expects.  Shares of  Eli Lilly  have trailed the market, and Novo\u2019s American depositary receipt is down roughly half over the past year, but analysts kept raising their estimates for sales of both company\u2019s top weight-loss drugs.  Why were the stocks underperforming if the growth outlook kept getting better?",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8957",
                "source": "Barrons.com",
                "ticker": "NVO",
                "title": "Wall Street Pulls Back on the Weight-Loss Drug Hype",
                "url": "https://finance.yahoo.com/m/d79f55fc-9d01-3b32-b923-bc52dea9e573/wall-street-pulls-back-on-the.html"
            },
            {
                "headline": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2732",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Here's Why Novo Nordisk (NVO) is a Strong Value Stock",
                "url": "https://finance.yahoo.com/news/heres-why-novo-nordisk-nvo-134008713.html"
            },
            {
                "headline": "Denmark\u2019s economy was reshaped by Novo Nordisk and obesity drugs. That identity now is under attack on multiple fronts, from science to geopolitics.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4767",
                "source": "Barrons.com",
                "ticker": "NVO",
                "title": "Novo Remade Denmark. Then Came the Stock Selloff.",
                "url": "https://finance.yahoo.com/m/8df06119-e6a9-3d0c-b1af-60987f9699ee/novo-remade-denmark-then.html"
            },
            {
                "headline": "The tariff war has prompted new calls to reshore manufacturing. Several large pharmas have already made the leap.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5994",
                "source": "Pharma Voice",
                "ticker": "NVO",
                "title": "Pharma\u2019s US manufacturing moment: Where companies are making the biggest moves",
                "url": "https://finance.yahoo.com/news/pharma-manufacturing-moment-where-companies-071322162.html"
            },
            {
                "headline": "Denmark\u2019s economy was reshaped by Novo Nordisk and obesity drugs. That identity now is under attack on multiple fronts, from science to geopolitics.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4767",
                "source": "Barrons.com",
                "ticker": "NVO",
                "title": "Novo Remade Denmark. Then Came the Stock Selloff.",
                "url": "https://finance.yahoo.com/m/8df06119-e6a9-3d0c-b1af-60987f9699ee/novo-remade-denmark-then.html"
            },
            {
                "headline": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2732",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Here's Why Novo Nordisk (NVO) is a Strong Value Stock",
                "url": "https://finance.yahoo.com/news/heres-why-novo-nordisk-nvo-134008713.html"
            }
        ],
        "avgScore": 0.0232
    },
    "4 10 2025": {
        "importantArticles": [
            {
                "headline": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4215",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
                "url": "https://finance.yahoo.com/news/2-medical-stocks-could-beat-130011780.html"
            },
            {
                "headline": "Procter & Gamble, Novo Nordisk, PepsiCo, Genie Energy and Canterbury Park are included in this Analyst Blog.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2732",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "The Zacks Analyst Blog Highlights Procter & Gamble, Novo Nordisk, PepsiCo, Genie Energy and Canterbury Park",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-procter-090000606.html"
            },
            {
                "headline": "Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might \"go wild\" on biotech stocks.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.",
                "url": "https://finance.yahoo.com/m/ad410584-ce11-3244-a597-6a1760bc9030/trump-wants-rfk-jr-to-go.html"
            },
            {
                "headline": "The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs",
                "url": "https://finance.yahoo.com/news/pharma-stocks-rebound-trump-announces-125400968.html"
            },
            {
                "headline": "The latest investor updates on stocks that are trending on Thursday.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Yahoo Finance UK",
                "ticker": "NVO",
                "title": "Trending tickers: TSMC, Trump Media, US Steel, Novo Nordisk and Tesco",
                "url": "https://finance.yahoo.com/news/tsmc-trump-media-us-steel-novo-nordisk-tesco-trending-tickers-094532440.html"
            },
            {
                "headline": "Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might \"go wild\" on biotech stocks.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.",
                "url": "https://finance.yahoo.com/m/ad410584-ce11-3244-a597-6a1760bc9030/trump-wants-rfk-jr-to-go.html"
            }
        ],
        "avgScore": 0.033600000000000005
    },
    "4 9 2025": {
        "importantArticles": [
            {
                "headline": "Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean investors should avoid buying stocks right now -- quite the contrary.  History tells us that equities tend to experience strong runs following downturns, so it's worth putting money into excellent companies that are being dragged down with along with the broader market.  To that end, let's consider five excellent growth-oriented companies to invest in on the dip: Novo Nordisk (NYSE: NVO), Eli Lilly (NYSE: LLY), Vertex Pharmaceuticals (NASDAQ: VRTX), Intuitive Surgical (NASDAQ: ISRG), and Shopify (NASDAQ: SHOP).",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9362",
                "source": "Motley Fool",
                "ticker": "NVO",
                "title": "5 Top Growth Stocks to Buy in the Stock Market Sell-Off",
                "url": "https://finance.yahoo.com/news/5-top-growth-stocks-buy-140000326.html"
            },
            {
                "headline": "Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novo Nordisk A/S (NVO) and PepsiCo, Inc. (PEP), as well as two micro-cap stocks Genie Energy Ltd. (GNE) and Canterbury Park Holding Corporation (CPHC).",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4939",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Top Analyst Reports for Procter & Gamble, Novo Nordisk & PepsiCo",
                "url": "https://finance.yahoo.com/news/top-analyst-reports-procter-gamble-205100046.html"
            },
            {
                "headline": "Pharma names whipsawed Wednesday after Trump said he would enact \"major\" tariffs on drug imports and then backed off his tariffs \u2014 for now.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0258",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Dow Jones, S&P 500 Pharma Names Recover After Trump Backs Off His Tariffs Plan",
                "url": "https://finance.yahoo.com/m/be7d1b24-7c1e-38ff-91b2-281ea7807568/dow-jones-s-p-500-pharma.html"
            },
            {
                "headline": "Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil.  AbbVie, Eli Lilly, Johnson & Johnson, Merck and Pfizer were all down at least 2.5% in Wednesday midday trading.  Denmark's Novo Nordisk, Switzerland's Novartis and the U.K.'s AstraZeneca and GSK fell 2% or more in the U.S.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7506",
                "source": "The Wall Street Journal",
                "ticker": "NVO",
                "title": "Novo Nordisk, AbbVie Stocks Slide After Trump Vows Pharma Tariffs",
                "url": "https://finance.yahoo.com/m/f171bfb7-94e2-3b98-bde2-9d5add357a5c/novo-nordisk-abbvie-stocks.html"
            },
            {
                "headline": "Catalysts host Madison Mills goes over some of the top stories of the day on this segment of Market Minute. Delta Air Lines (DAL) cut its full-year guidance as uncertainty around tariffs weighs on bookings. Walmart (WMT) walks back its first quarter profit guidance, citing tariff risks. Pharmaceutical stocks, including Pfizer (PFE), Novo Nordisk (NVO), and Eli Lilly (LLY), are under pressure after President Trump announced that there may be pharmaceutical tariffs underway. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4767",
                "source": "Yahoo Finance Video",
                "ticker": "NVO",
                "title": "Delta, Walmart, pharmaceutical stocks: Market Minute",
                "url": "https://finance.yahoo.com/video/delta-walmart-pharmaceutical-stocks-market-151538726.html"
            },
            {
                "headline": "The latest investor updates on stocks that are trending on Wednesday.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Yahoo Finance UK",
                "ticker": "NVO",
                "title": "Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca",
                "url": "https://finance.yahoo.com/news/apple-advanced-micro-devices-ford-bp-astrazeneca-trending-tickers-093254195.html"
            }
        ],
        "avgScore": 0.03265714285714284
    },
    "4 8 2025": {
        "importantArticles": [
            {
                "headline": "Both LLY and NVO are leading pharmaceutical companies specializing in diabetes and obesity treatments.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?",
                "url": "https://finance.yahoo.com/news/lly-vs-nvo-weight-loss-140900571.html"
            },
            {
                "headline": "Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1621",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-trending-stock-130012251.html"
            },
            {
                "headline": "Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: TRUMP SAYS NO INFLATION: President Trump said via Truth Social, \u201cOil prices are down, interest rates are down (the slow moving Fed should cut rates!), food prices are down, there is NO INFLATION, and the long time abused USA is bringing in Billions of Dollars a week from the abusing countries on",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.8155",
                "source": "TipRanks",
                "ticker": "NVO",
                "title": "Trump Trade: Trump claims \u2018no inflation,\u2019 Medicare won\u2019t cover obesity drugs",
                "url": "https://finance.yahoo.com/news/trump-trade-trump-claims-no-142755841.html"
            },
            {
                "headline": "Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: TRUMP SAYS NO INFLATION: President Trump said via Truth Social, \u201cOil prices are down, interest rates are down (the slow moving Fed should cut rates!), food prices are down, there is NO INFLATION, and the long time abused USA is bringing in Billions of Dollars a week from the abusing countries on",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.8155",
                "source": "TipRanks",
                "ticker": "NVO",
                "title": "Trump Trade: Trump claims \u2018no inflation,\u2019 Medicare won\u2019t cover obesity drugs",
                "url": "https://finance.yahoo.com/news/trump-trade-trump-claims-no-142755841.html"
            },
            {
                "headline": "Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1621",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-trending-stock-130012251.html"
            },
            {
                "headline": "Both LLY and NVO are leading pharmaceutical companies specializing in diabetes and obesity treatments.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?",
                "url": "https://finance.yahoo.com/news/lly-vs-nvo-weight-loss-140900571.html"
            }
        ],
        "avgScore": -0.3258666666666667
    },
    "4 7 2025": {
        "importantArticles": [
            {
                "headline": "Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better compete with rival Eli Lilly in the populous nation, two sources familiar with the plans told Reuters.  Novo, which had earlier planned for a 2026 launch of the drug, is now looking to begin selling Wegovy in India \"this year, probably in the next few months,\" sources told Reuters on condition of anonymity as they were not authorized to talk to the media.",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7783",
                "source": "Reuters",
                "ticker": "NVO",
                "title": "Novo preparing for early launch of weight-loss drug Wegovy in India",
                "url": "https://finance.yahoo.com/news/novo-preparing-early-launch-weight-152952920.html"
            },
            {
                "headline": "This decision is a blow for Eli Lilly and Novo Nordisk, who had both previously endorsed the proposed expansion.",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.25",
                "source": "Pharmaceutical Technology",
                "ticker": "NVO",
                "title": "Obesity drugs won\u2019t be covered by Medicare under 2026 CMS policy",
                "url": "https://finance.yahoo.com/news/obesity-drugs-won-t-covered-111330060.html"
            },
            {
                "headline": "The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration\u2019s focus on curbing government spending.",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2572",
                "source": "Healthcare Dive",
                "ticker": "NVO",
                "title": "Trump rejects Biden administration plan to let Medicare cover obesity drugs",
                "url": "https://finance.yahoo.com/news/trump-rejects-biden-administration-plan-095500389.html"
            },
            {
                "headline": "CMS keeps out LLY and NVO's obesity drugs from Medicare coverage. Medicare, at present, does not cover obesity drugs if they are solely prescribed for weight loss.",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "NVO & LLY Shares Down on Exclusion of Obesity Drugs From Medicare",
                "url": "https://finance.yahoo.com/news/nvo-lly-shares-down-exclusion-131400783.html"
            },
            {
                "headline": "The weight-loss drug war is heating up--and Novo just made its boldest move yet deep in Latin America.",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "GuruFocus.com",
                "ticker": "NVO",
                "title": "Novo Nordisk's $1B Power Play: Can Brazil Make or Break the Ozempic Empire?",
                "url": "https://finance.yahoo.com/news/novo-nordisks-1b-power-play-201720029.html"
            },
            {
                "headline": "The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration\u2019s focus on curbing government spending.",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2572",
                "source": "Healthcare Dive",
                "ticker": "NVO",
                "title": "Trump rejects Biden administration plan to let Medicare cover obesity drugs",
                "url": "https://finance.yahoo.com/news/trump-rejects-biden-administration-plan-095500389.html"
            }
        ],
        "avgScore": 0.02694000000000001
    },
    "4 4 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of 10 Best Beaten Down Stocks to Buy According to Analysts. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best beaten down stocks to buy according to analysts. JPMorgan released a market update where it highlighted the US Fed\u2019s [\u2026]",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5859",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Is Novo Nordisk A/S (NVO) The Best Beaten Down Stock to Buy According to Analysts?",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-best-beaten-144820190.html"
            },
            {
                "headline": "The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Eli Lilly, Novo Stocks Dive After Medicare Excludes Weight-Loss Drugs",
                "url": "https://finance.yahoo.com/m/6276abb5-892d-34ad-bd69-384498b138a5/eli-lilly-novo-stocks-dive.html"
            },
            {
                "headline": "Eli Lilly stock has sold off alongside the broader market over the last week, undercutting its moving averages. Is LLY stock a sell?",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?",
                "url": "https://finance.yahoo.com/m/75ad41f4-79f0-3b48-af19-38b6a6e1e059/eli-lilly-reverses-its-recent.html"
            },
            {
                "headline": "The Trump administration has decided not to back a Biden administration plan that would have allowed Medicare to pay for obesity drugs, according to a report from Bloomberg. Shares of both Eli Lilly (LLY) and Novo Nordisk (NVO) traded lower on the news. Learn more in the video above. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here.",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1027",
                "source": "Yahoo Finance Video",
                "ticker": "NVO",
                "title": "Trump admin. to reportedly drop Medicare GLP-1 plan",
                "url": "https://finance.yahoo.com/video/trump-admin-reportedly-drop-medicare-211717981.html"
            },
            {
                "headline": "Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO), reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for 2024. Novo Holdings owns 28.1% shares in Novo ...",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "-0.0258",
                "source": "Benzinga",
                "ticker": "NVO",
                "title": "Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales",
                "url": "https://finance.yahoo.com/news/novo-nordisk-stakeholder-reports-9-013028787.html"
            },
            {
                "headline": "Eli Lilly stock has sold off alongside the broader market over the last week, undercutting its moving averages. Is LLY stock a sell?",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?",
                "url": "https://finance.yahoo.com/m/75ad41f4-79f0-3b48-af19-38b6a6e1e059/eli-lilly-reverses-its-recent.html"
            }
        ],
        "avgScore": 0.09147999999999998
    },
    "4 3 2025": {
        "importantArticles": [
            {
                "headline": "Artisan Partners, an investment management company, released its \u201cArtisan Global Opportunities Fund\u201d fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. US equities experienced significant gains in Q4, showcasing a strong year. The portfolio showed slight weakness in Q4 but posted a strong absolute return in 2024. In the fourth [\u2026]",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8225",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Artisan Global Opportunities Fund Trimmed its Position in Novo Nordisk A/S (NVO)",
                "url": "https://finance.yahoo.com/news/artisan-global-opportunities-fund-trimmed-114310970.html"
            },
            {
                "headline": "Novo Nordisk (NVO) closed at $67.10 in the latest trading session, marking a -1.67% move from the prior day.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Novo Nordisk (NVO) Stock Moves -1.67%: What You Should Know",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-stock-moves-214514258.html"
            },
            {
                "headline": "Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday. Novo's rare disease unit head, Ludovic Helfgott, who was already on the executive management team, will immediately assume the responsibility for product and portfolio strategy, including commercial strategy, medical affairs and business development across all therapy areas, the company said. Sylvest was one of two women on Novo's 10-person executive management team.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0516",
                "source": "Reuters",
                "ticker": "NVO",
                "title": "Novo Nordisk's head of commercial strategy steps down",
                "url": "https://finance.yahoo.com/news/novo-nordisks-head-commercial-strategy-063544371.html"
            },
            {
                "headline": "Bagsv\u00e6rd, Denmark, 3 April 2025 \u2013 Novo Nordisk today announced the following changes in Executive Management. After a distinguished career of 28 years with Novo Nordisk, hereof seven years as executive vice president of Commercial Strategy & Corporate Affairs, Camilla Sylvest has decided to leave the company. Consequently, as of 3 April 2025, the following organisational changes are implemented: Ludovic Helfgott, executive vice president, Rare Disease, will assume the responsibility for Product",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0516",
                "source": "GlobeNewswire",
                "ticker": "NVO",
                "title": "Novo Nordisk announces changes in Executive Management",
                "url": "https://finance.yahoo.com/news/novo-nordisk-announces-changes-executive-060000828.html"
            },
            {
                "headline": "Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday. Novo's rare disease unit head, Ludovic Helfgott, who was already on the executive management team, will immediately assume the responsibility for product and portfolio strategy, including commercial strategy, medical affairs and business development across all therapy areas, the company said. Sylvest was one of two women on Novo's 10-person executive management team.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0516",
                "source": "Reuters",
                "ticker": "NVO",
                "title": "Novo Nordisk's head of commercial strategy steps down",
                "url": "https://finance.yahoo.com/news/novo-nordisks-head-commercial-strategy-063544371.html"
            },
            {
                "headline": "Novo Nordisk (NVO) closed at $67.10 in the latest trading session, marking a -1.67% move from the prior day.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Novo Nordisk (NVO) Stock Moves -1.67%: What You Should Know",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-stock-moves-214514258.html"
            }
        ],
        "avgScore": 0.179825
    },
    "4 2 2025": {
        "importantArticles": [
            {
                "headline": "Drugmakers breathed a sigh of relief Wednesday after President Trump didn\u2019t announce pharmaceutical tariffs.  Plus, language in the executive order indicated medicines were exempted from the reciprocal tariffs that Trump did announce.  Drugmakers were combing over the executive order to clarify the exemption language in the executive order and to make sure they won\u2019t be hit by any other tariff provisions, such as the 10% \u201cbaseline\u201d tariff.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6705",
                "source": "The Wall Street Journal",
                "ticker": "NVO",
                "title": "Big Pharma Avoids Worst-Case Tariff Scenario",
                "url": "https://finance.yahoo.com/m/06d142db-a905-336a-a0df-f505312c37de/big-pharma-avoids-worst-case.html"
            },
            {
                "headline": "The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2263",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?",
                "url": "https://finance.yahoo.com/news/lxrx-stock-moves-30-week-141800883.html"
            },
            {
                "headline": "Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and investment returns in 2024.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Quartz",
                "ticker": "NVO",
                "title": "Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump",
                "url": "https://finance.yahoo.com/news/novo-holdings-earnings-nearly-doubled-151300670.html"
            },
            {
                "headline": "Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2732",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch",
                "url": "https://finance.yahoo.com/m/0a24e75b-02ee-3b96-9b67-944a285506f5/hims-claws-back-after-its.html"
            },
            {
                "headline": "Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and investment returns in 2024.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Quartz",
                "ticker": "NVO",
                "title": "Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump",
                "url": "https://finance.yahoo.com/news/novo-holdings-earnings-nearly-doubled-151300670.html"
            },
            {
                "headline": "The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2263",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?",
                "url": "https://finance.yahoo.com/news/lxrx-stock-moves-30-week-141800883.html"
            }
        ],
        "avgScore": 0.1559
    },
    "4 1 2025": {
        "importantArticles": [
            {
                "headline": "Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings to offset any impact from impending restrictions on selling copies of Novo Nordisk's obesity drug.  Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded versions of Lilly's tirzepatide \u2014 the active ingredient in weight-loss drug Zepbound and diabetes medicine Mounjaro \u2014 and generics of Novo's diabetes drug, liraglutide.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7351",
                "source": "Reuters",
                "ticker": "NVO",
                "title": "Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform",
                "url": "https://finance.yahoo.com/news/hims-hers-sell-lillys-weight-173933173.html"
            },
            {
                "headline": "The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3182",
                "source": "Motley Fool",
                "ticker": "NVO",
                "title": "Where Will Eli Lilly Be in 1 Year?",
                "url": "https://finance.yahoo.com/news/where-eli-lilly-1-093700057.html"
            },
            {
                "headline": "Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Hims Stock Jumps After Adding Eli Lilly's Obesity Drug To Its Platform",
                "url": "https://finance.yahoo.com/m/877a443d-016e-3f73-9182-44a3661c599e/hims-stock-jumps-after-adding.html"
            },
            {
                "headline": "Investing.com -- Barclays has lowered its first-quarter 2025 estimates for Novo Nordisk (CSE:NOVOb) (NYSE:NVO) ahead of its Q1 2025 report, citing weaker-than-expected prescription volumes for key drugs Wegovy and Ozempic in the U.S.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.128",
                "source": "Investing.com",
                "ticker": "NVO",
                "title": "Barclays cuts Novo Nordisk estimates on lower Wegovy, Ozempic volumes in the U.S.",
                "url": "https://finance.yahoo.com/news/barclays-cuts-novo-nordisk-estimates-140717529.html"
            },
            {
                "headline": "Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Hims Stock Jumps After Adding Eli Lilly's Obesity Drug To Its Platform",
                "url": "https://finance.yahoo.com/m/877a443d-016e-3f73-9182-44a3661c599e/hims-stock-jumps-after-adding.html"
            },
            {
                "headline": "The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3182",
                "source": "Motley Fool",
                "ticker": "NVO",
                "title": "Where Will Eli Lilly Be in 1 Year?",
                "url": "https://finance.yahoo.com/news/where-eli-lilly-1-093700057.html"
            }
        ],
        "avgScore": 0.23132499999999998
    },
    "3 31 2025": {
        "importantArticles": [
            {
                "headline": "DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes",
                "url": "https://finance.yahoo.com/news/dxcm-inks-deal-nanowear-boost-133000845.html"
            },
            {
                "headline": "The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Pharma Voice",
                "ticker": "NVO",
                "title": "In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly",
                "url": "https://finance.yahoo.com/news/obesity-triple-agonist-blockbuster-race-072319136.html"
            },
            {
                "headline": "(Bloomberg) -- As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.Most Read from BloombergGold-Rush Fever Returns to Historic New Zealand Mining TownWhat Frank Lloyd Wright Learned From the DesertBank Regulators Fight for Desks as OCC Returns to New York TowerThese US Bridges Face High Risk of Catastrophic Ship StrikesCharter Schools, Colleges Push Muni Debt Distress",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.9153",
                "source": "Bloomberg",
                "ticker": "NVO",
                "title": "Novo Nordisk\u2019s Worst Month Since 2002 Shows Growth Concerns",
                "url": "https://finance.yahoo.com/news/novo-nordisk-worst-month-since-101148181.html"
            },
            {
                "headline": "(Bloomberg) -- As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.Most Read from BloombergGold-Rush Fever Returns to Historic New Zealand Mining TownWhat Frank Lloyd Wright Learned From the DesertBank Regulators Fight for Desks as OCC Returns to New York TowerThese US Bridges Face High Risk of Catastrophic Ship StrikesCharter Schools, Colleges Push Muni Debt Distress",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.9153",
                "source": "Bloomberg",
                "ticker": "NVO",
                "title": "Novo Nordisk\u2019s Worst Month Since 2002 Shows Growth Concerns",
                "url": "https://finance.yahoo.com/news/novo-nordisk-worst-month-since-101148181.html"
            },
            {
                "headline": "The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Pharma Voice",
                "ticker": "NVO",
                "title": "In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly",
                "url": "https://finance.yahoo.com/news/obesity-triple-agonist-blockbuster-race-072319136.html"
            },
            {
                "headline": "DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes",
                "url": "https://finance.yahoo.com/news/dxcm-inks-deal-nanowear-boost-133000845.html"
            }
        ],
        "avgScore": -0.48066666666666663
    },
    "3 28 2025": {
        "importantArticles": [
            {
                "headline": "We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other best ADR stocks. American Depositary Receipts (ADR) are US-listed securities that represent shares in foreign companies, allowing American [\u2026]",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9153",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Is Novo Nordisk (NVO) the Best ADR Stock to Buy According to Hedge Funds?",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-best-adr-212550945.html"
            },
            {
                "headline": "Novo Nordisk is making more moves to strengthen its position as a leader in the obesity treatment market.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3744",
                "source": "Pharmaceutical Technology",
                "ticker": "NVO",
                "title": "Novo Nordisk strikes $1bn deal for Lexicon\u2019s oral obesity drug",
                "url": "https://finance.yahoo.com/news/novo-nordisk-strikes-1bn-deal-170408450.html"
            },
            {
                "headline": "Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.34",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know",
                "url": "https://finance.yahoo.com/news/investors-heavily-search-novo-nordisk-130013448.html"
            },
            {
                "headline": "Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could prompt the Danish drugmaker to cut its 2025 guidance in its quarterly results.  BofA global research predicted in a note a 2% cut to the company's full-year sales guidance and expects a new sales growth range for the year of between 14% and 22%.  \"1Q seems a possible miss on sluggish Ozempic/Wegovy trends, worse currency (impact) and possibly higher (selling, general and administrative expenses) needed for demand creation and to convince physicians that supply is back,\" BofA said.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5423",
                "source": "Reuters",
                "ticker": "NVO",
                "title": "BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag",
                "url": "https://finance.yahoo.com/news/bofa-says-novo-nordisk-may-124125031.html"
            },
            {
                "headline": "Investing.com -- Bank of America (BofA) on Friday lowered its price target for Novo Nordisk (CSE:NOVOb)k (NYSE:NVO) shares, cautioning that the company may miss its first-quarter earnings projections as sales of its megahit drugs Wegovy and Ozempic, lag.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "Investing.com",
                "ticker": "NVO",
                "title": "BofA cuts Novo Nordisk shares target on expected Q1 earnings miss",
                "url": "https://finance.yahoo.com/news/bofa-cuts-novo-nordisk-shares-135421763.html"
            },
            {
                "headline": "Novo Nordisk will pay Lexicon Pharmaceuticals up to $1 billion to license its experimental obesity treatment.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1027",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Novo Nordisk Inks Its Second Big Obesity Deal In A Week \u2014 And It's Not For A GLP-1",
                "url": "https://finance.yahoo.com/m/37f312c0-b1a2-341e-8db3-6e35681e8002/novo-nordisk-inks-its-second.html"
            }
        ],
        "avgScore": 0.09521428571428572
    },
    "coef": -0.4107142857142856,
    "avgCoef": 0.03183572498710902,
    "similar": {
        "HTZ": 0.3,
        "ABEV": 0.07864167572767856,
        "AAL": 0.04285714285714285,
        "WBD": 0.035714285714285705
    }
}